Loading…
← CockpitCompetitor Analysis › 600976.SS JIANMIN PHARMACEUTICAL GROUP CO LTD. Class AOpen in the cockpit ↗

JIANMIN PHARMACEUTICAL GROUP CO LTD. Class A600976.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum strong 74
Mkt cap
$598M
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$6.53M
20-day average traded
Fwd P/E
6.7×
forward earnings
ROIC−WACC
+7.7 pp
WACC 6.8%
Hurdle
-13 pp
Req g minus delivered
Next earnings
120 days
18 Mar 2027
Close · CNYCN¥26.39
1D-2.6%
1W-5.1%
1M-2.9%
3M-11.5%
6M-14.2%
YTD-21.4%
1Y-33.0%
ATR %2.6%
52w lowhigh34.5% off high

What JIANMIN PHARMACEUTICAL does

Employees: 2,257

JIANMIN PHARMACEUTICAL at a glance

Size JIANMIN PHARMACEUTICAL (600976.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $598M, the 3250th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥26.39 on 18 Nov 2026.

Performance Over six months the shares fell 14.2%, against -31.3% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue fell 1.7% over the last twelve months (peer median +2.9%); the operating margin is 8.1% (peer median 2.2%).

Valuation It trades at 6.7× forward earnings against a peer median of 26.8× (2nd cheapest of 8).

Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -13 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 7.7 points above its cost of capital (6.8% WACC).

Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026600976.SS 87Peer median 71
Six months, rebased to 100: JIANMIN PHARMACEUTICAL against the median of its 20 peers (local-currency closes).

JIANMIN PHARMACEUTICAL financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.12BCN¥3.35BCN¥3.48BCN¥4.18BCN¥3.62B
Revenue growth—-4%-17%+16%—
Gross profitCN¥1.86BCN¥1.91BCN¥1.61BCN¥1.88BCN¥1.52B
EBITDAn/aCN¥302MCN¥181MCN¥372MCN¥300M
Net incomeCN¥312MCN¥360MCN¥362MCN¥521MCN¥408M
Free cash flowCN¥418MCN¥174MCN¥311MCN¥307MCN¥323M
Capital expenditureCN¥104MCN¥101MCN¥120MCN¥64.5MCN¥68.0M
Total debtCN¥245MCN¥292MCN¥397MCN¥501MCN¥367M

Quarterly statements and history in the cockpit →

JIANMIN PHARMACEUTICAL competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-25%0%+25%+50%IMMX301096300233DBV300147185750002793002940300194CGEMORCHPHARMA60343941052157OLMA3012112256600976.SS6-month return →1-month return →
Up and to the right = strong over both horizons. JIANMIN PHARMACEUTICAL is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×25×50×75×301096185750603567ORCHPHARMA60343941052157600976.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. JIANMIN PHARMACEUTICAL is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-25%0%25%50%3002333001471857500027936035670029403001946034394105600976.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. JIANMIN PHARMACEUTICAL is the large dot.

JIANMIN PHARMACEUTICAL competitors and peer comparison

How JIANMIN PHARMACEUTICAL compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

JIANMIN PHARMACEUTICAL against its 20 peers (data as of 18 Nov 2026)
Measure600976.SSPeer medianRank in peer set
1-month return-2.9%-11.8%6th highest of 20
6-month return-14.2%-31.3%6th highest of 20
Distance from 52-week high-34.5%-44.1%4th highest of 20
Revenue growth (TTM)-1.7%+2.9%7th lowest of 16
Operating margin8.1%2.2%3rd highest of 15
Forward P/E6.7×26.8×2nd cheapest of 8
Growth the price implies (Req g, 7 yrs)-6.2%9.1%3rd least demanding of 10
Growth delivered (Del g)+6.5%-1.6%3rd highest of 10
Hurdle (Req g minus delivered)-12.7 pp+8.1 pp2nd least demanding of 10
ROIC minus cost of capital+7.7 pp-5.4 pp2nd highest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%6.7×-6.2%+6.5%
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%54.0×n/an/a
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%n/a-0.6%-1.6%
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%n/a50.4%-12.3%
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%11.4×-6.6%+5.4%
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%n/a-1.0%-17.9%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a5.4×9.1%-25.1%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%n/a10.1%+2.1%
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%n/a10.9%-5.9%
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%83.1×n/an/a
GuiZhou SanLi Pharmaceutical 603439.SSChina$583M-20%-6%5%26.8×20.9%+21.9%
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%10.2×-8.7%+8.8%
Lepu Biopharma 2157.HKHong Kong$580M-43%+47%7%53.6×n/an/a
Oneness Biotech 4743.TWOTaiwan$580M-13%+19%-589%n/an/an/a
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%n/an/an/a
Abbisko Cayman 2256.HKHong Kong$578M-39%-83%-520%n/an/an/a

Questions

Which companies are JIANMIN PHARMACEUTICAL's closest peers?
The cockpit's peer set: Immix Biopharma (IMMX), Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ), Shandong Jincheng Pharmaceutical (300233.SZ), DBV Technologies (DBV.PA), Xiangxue Pharmaceutical (300147.SZ), Chongkundang (185750.KS), Luoxin Pharmaceuticals Group Stock (002793.SZ), Achieve Life Sciences (QUIT).
Is JIANMIN PHARMACEUTICAL expensive compared with its peers?
On forward p/e it trades at 6.7× against a peer median of 26.8×, 2nd cheapest of 8 in its peer set. For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +7%, so the hurdle is -13 pp: the price already allows for a slowdown.
How has JIANMIN PHARMACEUTICAL stock performed?
Over six months to 18 Nov 2026 the shares returned -14.2% against -31.3% for the median peer; over one year -33.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.